AMGN vs VRDN: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AMGN is the larger of the two ($237.84B market cap): the incumbent the market prices for continued execution (17.53x forward earnings, beta 0.42). VRDN is the smaller challenger ($3.48B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, VRDN fits: analysts expect its revenue to rise 324% next year, against 5% for AMGN. If you believe in profit, AMGN fits: it is expected to make money next year (17.53x forward earnings), while VRDN is still expected to post a loss.
AMGN vs VRDN: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AMGN | VRDN | What it tells you |
|---|---|---|---|
| Market cap | $237.84B | $3.48B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 17.53 | -14.83 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.42 | 1.07 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 74% of range | 83% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 16.57 | 7.21 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AMGN and VRDN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMGN and VRDN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMGN and VRDN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Amgen (AMGN) do?
Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.
What does Viridian Therapeutics (VRDN) do?
Viridian Therapeutics (Nasdaq: VRDN) is a biopharmaceutical company focused on thyroid eye disease (TED), a rare autoimmune condition that causes eye bulging (proptosis) and double vision (diplopia). Its lead drug, Lumvoa (veligrotug-vvze), is an intravenous anti-IGF-1R antibody that the FDA approved in June 2026 for both active and chronic TED, based on the THRIVE and THRIVE-2 phase 3 trials. The company is also developing subcutaneous elegrobart (an autoinjector TED candidate with positive REVEAL-1 and REVEAL-2 phase 3 data and a BLA filing on track for the first quarter of 2027) and an earlier-stage FcRn portfolio (VRDN-006 and VRDN-008).
AMGN vs VRDN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.
- VRDN drivers: Lumvoa launch and TED market share; Subcutaneous elegrobart pipeline.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. For VRDN, viridian is a newly commercial biotech with early product revenue (~$24.7 million in its first full quarter) and quarterly net losses around $100 million (~$101 million in Q3 2026, ~$398 million over the trailing twelve months), so its valuation depends heavily on future sales that have not yet materialized.
AMGN or VRDN: which should you pick?
If the story you believe is AMGN's (Rare disease and Horizon assets), AMGN is the more direct way to own it; if it is VRDN's (Lumvoa launch and TED market share), VRDN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMGN and VRDN guides.
AMGN vs VRDN: the full fundamentals
AMGN. As of November 20, 2026, Amgen trades at about 25x trailing GAAP earnings and about 17.5x forward earnings, with EV/EBITDA near 16x, a higher multiple than early 2026 after the shares gained about a third. The dividend yield is about 2.3%. The next report is expected around February 2, 2027, with consensus for the December quarter of adjusted EPS near $5.61 on about $10.48 billion of revenue; the 29 analysts covering the stock rate it a Hold on average, with a mean target of about $436, close to the current price.
VRDN. As of November 20, 2026, Viridian carried a roughly $3.5 billion market cap against ~$26 million of trailing revenue, nearly all of it from Lumvoa's first full quarter, so the ~132x price-to-sales figure says little about the launch. The valuation rests on expectations for TED sales (consensus ~$50 million in Q4 2026 and ~$323 million in 2027) and on a cash balance near $955 million that funds continuing losses.
Headline figures (approximate, November 2026): AMGN shows revenue (ttm) ~$38.9 billion, revenue growth (q3 2026, yoy) ~8.5%, operating margin ~34%, net income (ttm) ~$9.4 billion; VRDN shows revenue (ttm) ~$26M, almost all Lumvoa sales in Q3 2026, lumvoa net product revenue (q3 2026) ~$24.7M vs ~$4.7M consensus revenue, net loss (ttm) ~$398M; Q3 2026 ~$101M, eps (q3 2026) -$0.81 vs -$1.02 consensus.
The bottom line: AMGN vs VRDN
AMGN and VRDN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AMGN and VRDN exposure against your real portfolio. It is not an investment adviser.
Wondering how AMGN or VRDN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Amgen
Ask Walnut's AI anything about AMGN and see how it fits what you own.
FAQ
What is the difference between AMGN and VRDN?
+
Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Viridian Therapeutics (Nasdaq: VRDN) is a biopharmaceutical company focused on thyroid eye disease (TED), a rare autoimmune condition that causes eye bulging (proptosis) and double vision (diplopia). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AMGN or VRDN the better stock?
+
Neither is universally better. AMGN is the larger incumbent; VRDN is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AMGN or VRDN?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AMGN and VRDN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AMGN vs VRDN?
+
AMGN: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including MariTide and its other obesity programs, can fail in late-stage trials or face regulatory setbacks. Newer franchises face their own competition, such as Viridian's Lumvoa against Tepezza. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition left Amgen with about $54 billion of total debt against about $13 billion of cash as of September 30, 2026. After a 34% year-to-date gain the share price of about $440 sits near the ~$436 average analyst target (Mizuho's target is $388 with a Neutral rating), and consensus expects about 8% EPS growth in 2026 and 6.5% in 2027, so the valuation already assumes steady execution. Litigation, manufacturing, and safety risks are inherent to the industry. VRDN: Viridian is a newly commercial biotech with early product revenue (~$24.7 million in its first full quarter) and quarterly net losses around $100 million (~$101 million in Q3 2026, ~$398 million over the trailing twelve months), so its valuation depends heavily on future sales that have not yet materialized. Lumvoa faces direct competition from Amgen's Tepezza, an entrenched incumbent that is also developing a subcutaneous formulation, and launch uptake, pricing, reimbursement, and physician adoption are all uncertain. The company is concentrated in thyroid eye disease, a rare-disease market, so any safety signal, slow launch, or competitive setback would weigh heavily. Pipeline programs like elegrobart and the FcRn portfolio carry clinical and regulatory risk, and continued losses could eventually require additional capital that dilutes shareholders. The stock has already shown that sensitivity, trading in a 52-week range of roughly $13 to $34 and gaining ~37% in the single month after the Q3 report, which raises the bar for the next quarters. Broad payer coverage is only targeted six to nine months after launch, and management has said it is too early to confirm a sustained trend.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMGN or VRDN; figures are approximate and dated (as of November 2026). Verify current data before investing.